Retrospective cohort links IINS and RLR to survival in esophageal cancer surgery patientsNew blood markers may help predict survival after esophageal cancer surgery

Frontiers in Medicine Published April 16, 2026 Study authors: Huike Wang, Zhe Wang, Bingtong Yue, Xi Luo, Yalan Yang, Yu Chen, Feng Wang DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note IINS and RLR as prognostic indicators for esophageal cancer survival, with caution regarding validation.

This retrospective cohort study included 660 esophageal cancer patients who underwent radical surgery. The investigation assessed the inflammation–immunity–nutrition score (IINS) and red cell distribution width-to-lymphocyte ratio (RLR) as potential prognostic indicators for patient outcomes. The primary outcome measured was postoperative survival. No specific follow-up duration was reported in the available data provided for this analysis. The setting was not reported. The study phase was not reported.

IINS, RLR, and eight additional factors were identified as independent prognostic variables within the cohort. A nomogram incorporating these metrics showed superior discrimination versus AJCC staging. Statistical analysis indicated higher C-index and AUC in both cohorts. Additionally, DCA, IDI, and NRI confirmed greater net benefit and improved risk reclassification for the proposed model. These metrics were evaluated against standard staging methods to assess clinical utility.

Safety data regarding adverse events, serious adverse events, discontinuations, or tolerability were not reported. The study authors note that External multicenter validation is warranted. Current evidence supports individualized risk stratification and perioperative optimization. These findings may inform patient selection for immunotherapy, though causality cannot be established from this retrospective cohort design. Clinicians should interpret these results with caution regarding generalizability and confirmatory studies. The study does not report funding or conflicts of interest. The publication type was not reported.

This study looked at 660 patients who underwent radical surgery for esophageal cancer. Researchers examined blood markers called the inflammation–immunity–nutrition score and the red cell distribution width-to-lymphocyte ratio. They compared these markers against the standard AJCC staging system used to describe cancer spread.

The results showed that the new blood markers were independent predictors of survival. A model using these markers showed better ability to distinguish between patients with different outcomes than the standard system. Additional tests confirmed that using these markers provided a net benefit for risk assessment.

The study suggests these tools could support individualized risk stratification and perioperative optimization. They might also help inform patient selection for immunotherapy. However, the authors note that external multicenter validation is warranted. Because this was a retrospective study, the findings need confirmation in other settings before they are widely adopted.

What this means for you:

New blood markers predicted survival better than standard staging in one group of esophageal cancer patients, but need further testing.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedApr 2026

View Original Abstract ↓

Systemic inflammation, immunity, and nutritional status are integral to tumor biology, shaping the microenvironment and influencing esophageal cancer (EC) outcomes. Yet, their integration into pragmatic prognostic tools—and potential implications for immunotherapy stratification—remain limited. This retrospective study assessed the prognostic value of the inflammation–immunity–nutrition score (IINS) and red cell distribution width-to-lymphocyte ratio (RLR), indicators reflecting host immunity, systemic inflammation, and nutritional reserve, in EC patients. Clinical data from 660 EC patients who underwent radical surgery (2012–2018) were retrospectively analyzed and randomly assigned to training (n = 459) and validation (n = 201) cohorts. Candidate predictors were screened using LASSO and entered into multivariable Cox models. A nomogram incorporating IINS, RLR, and clinical covariates was constructed and validated with the C-index, calibration, and time-dependent AUC; clinical utility was evaluated with decision curve analysis (DCA), Integrated Discrimination Improvement (IDI), and Net Reclassification Index (NRI). IINS, RLR, and eight additional factors were independent prognostic variables. The nomogram showed good calibration and superior discrimination versus AJCC staging, with a higher C-index and AUC in both cohorts. DCA, IDI, and NRI confirmed greater net benefit and improved risk reclassification. This study proposes and internally validates a nomogram linking immune–nutritional surrogates with survival in EC. By reflecting systemic inflammation and host immunity, the model supports individualized risk stratification, perioperative optimization, and may inform patient selection for immunotherapy. External multicenter validation is warranted.

Retrospective cohort links IINS and RLR to survival in esophageal cancer surgery patientsNew blood markers may help predict survival after esophageal cancer surgery

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Retrospective cohort links IINS and RLR to survival in esophageal cancer surgery patientsNew blood markers may help predict survival after esophageal cancer surgery

More on Cancer

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties